AIM: Hypertension, hypervolemia and hemodilution therapy is a common approach to cerebral vasospasm after subarachnoid haemorrhage. This study is designed to see the difference of moderate or aggressive hypervolemia supported with induced hypertension in symptomatic vasospasm detected with transcranial Doppler ultrasonography (TCD) measurements.
InTRoduCTIon
Hyperdynamic therapy with hypervolemia, hypertension and hemodilution is used in many institutions for prophylaxis and treatment of symptomatic vasospasm. Vasospasm needs to be predicted and prevented due to neurologic complications. (3,10). However, the argument is still going on about the indication, modality, degree and risk/benefit ratio of triple H therapy (17, 24, 29) . The goal of triple H therapy in aneurysmal subarachnoid hemorrhage (SAH) is to manipulate circulating volume with volume expansion, blood pressure augmentation, assure oxygenation and blood viscosity to enhance cerebral blood flow in the setting of vasoconstriction (17, 35) . TCD offers an easy method for patients with SAH to detect the elevated flow velocities in basal cerebral arteries and identify the patients at risk of neurological deficits due to vasospasm (31) . Although some investigators advocate volume expansion for the treatment of vasospasm, the data about volume expansion is inconclusive in the literature. The
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present study is postulated to compare induced hypertension and moderate hypervolemia with induced hypertension and aggressive hypervolemia on cerebral blood flow velocities focusing on the efficacy of triple H therapy.
MATERIAL and METHodS
The study was performed in the neurointensive care unit of Goztepe Training Hospital in a period of two years (2007) (2008) (2009) . With the approval of institutional review board and after obtaining informed consents, a retrospective and prospective study of 58 patients with SAH who had developed vasospasm postoperatively was conducted. The exclusion criteria were traumatic and nonaneurysmal SAH, aneurysmal SAH with no symptoms of vasospasm, congestive heart failure and renal insufficiency. The aneurysmal SAH was documented by cranial tomography (CT) and angiography in all patients. Whenever possible, the patients had surgery to clip the ruptured aneurysm before SAH day 3. Hunt Hess classification, Fisher grade and Glasgow Coma Scale and Glasgow Outcome Scale (3 months) of the patients were recorded (6,9,11,33). 
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analysis was used for mean, standard deviation, minimum and maximum variables. Chi-Square test was used for the comparison between the two groups. Continuous variables were compared with 2-tailed t test and the significance level was recorded as p < 0.05.
RESuLTS
Fifty-eight SAH patients were treated to overcome vasospasm and followed up during 14 days. The details about age, gender, GCS, Hunt-Hess classification, Fisher Grade and location of the aneurysm are in Table I .
There was no difference between the two groups when compared according to GCS, Fisher Grade, Hunt-Hess classification, insulin requirement, CVP and outcome (p > 0.05) ( Table I) .
Compared with HNT group, HHT patients had a significantly higher fluid intake in 24 hours (p<0.05) but no difference in fluid balance was detected (p>0.05) (Figures 1, 2 ).
Through the study period of 14 days, with the induced hypertension, there was no difference observed in MAP measurements ( Figure 3) . Mean values of everyday measurements of MCA mFV of the two groups in 14 days presented significance in the first five days but there was no difference in the following days (Figure 4 ).
Hct recordings presented no distinction in the mean values ( Figure 5 ).
There were no differences in the frequency of the complications. Dilutional hyponatremia (< 135 mEq/L) occurred in only 3 patients and pulmonary edema in one patient in HHT. Infarction on CT scan was observed in 5 patients in HHT group and 4 patients in HNT group.
dISCuSSIon
Cerebral vasospasm is the delayed narrowing of large capacitance arteries of the base of the brain after SAH (1). It is the most common cause of morbidity and mortality following SAH, as it occurs in a delayed fashion, it should be prevented and treated with aggressive strategies (10,12,13,17,21,28,37). Triple H therapy is being utilized for prophylaxis and treatment of vasospasm and stroke complicating SAH and it is stated that this approach may decrease mortality and morbidity (level of evidence IIa, Grade B recommendation) (1,29).
The first step is to maintain adequate volume status because the patient is hypovolemic due to aneurysmal bleeding and hypothalamic dysfunction and secretion of natriuretic peptides (34) . But, most of the literature suggests that output is expected to increase the blood pressure and CBF. Hypertension will be achieved with volume expansion but vasoactive drugs may be used also for the targeted levels (17) .
In a study of 28 SAH patients of Manno et al. hypertension was induced with phenylephrine. In the majority of the patients with disturbed autoregulation, TCD velocities were altered by the manipulation of blood pressure (15) .
Following SAH, the blood pressure augmentation is disrupted and cerebral blood pressure becomes pressure oriented. In a study, systolic blood pressure was augmented with dopamine and subcutaneous vasopressin to levels between 150-175 mm Hg and cerebral blood flow and outcome have improved (34) .
In the observational study using microdialysis and brain oxygen monitoring, it was demonstrated that a hemoglobin concentration lower than 9 gr/dl is associated with brain hypoxia and cell energy dysfunction in patients with poor grade aneurysmal SAH (20 McGirt et al. showed that in 70 % of SAH patients, TCD could detect vasospasm on average 2.5 days before the onset of neurological deficits (16) .TCD may be useful to follow vasospasm progression, giving the chance for prophylactic treatment and guide the therapy employed for vasospasm (25).
The study findings
In the present study, triple H therapy was aimed to treat vasospasm in SAH patients. In order to reach the targeted values of mean arterial pressure in the first 23 patients, vasopressors were required extremely to support the hypervolemic therapy. Following the observation of 23 patients, the study was designed as a retrospective and a prospective one, to evaluate the effects of hypervolemia and normovolemia with induced hypertension. The main goal of hypervolemia was to increase the blood pressure. In the hypervolemia group, the mean fluid intake was 8105 ± 399.12 and there was a significant difference between the hypervolemia is not really achieved to change the cerebral blood flow, in addition it has many side effects and the benefits of hypervolemia are not detailed (14, 29, 35) .
Even though the components of triple-H therapy aim to increase cerebral perfusion and as a result improve the outcome, there have been a few randomized clinical trials on the effectiveness of triple-H therapy. In the systematic review of Dankabaar et al. isovolemic hemodilution or hypervolemia do not seem to improve cerebral blood flow but induced hypertension alone or with hypervolemia have improved cerebral blood flow in some studies (2).
Gupta et al. have studied on 25 patients with SAH to whom they performed triple-H therapy. They have started triple-H after detection of vasospasm with TCD recordings. Hypokalemia, haemorrhagic infarct, septicemia have occurred as complications. They have concluded that triple-H therapy is useful in vasospasm induced ischemic deficits, but in the presence of acute infarcts, it worsens brain edema; and in addition, intracranial pressure monitoring is advised in order to evaluate the components of triple-H therapy (7).
Despite the widespread use of triple H therapy to prevent vasospasm after SAH, only a few studies have questioned its efficacy and there is insufficient data of evidence based medicine to make recommendations for the preventive use of triple H therapy in SAH patients (26, 36) .
In a study of 82 SAH patients treated with hypervolemia or normovolemia, even though the cardiac filling pressures and fluid intake were higher in hypervolemia group, increase in blood volume or cerebral blood flow measurements have not presented any difference between the two groups (14).
Raabe et al. investigated the effects of hypervolemia and hypertension on brain tissue oxygenation in 45 SAH patients. Moderate hypertension caused the highest increase in brain tissue oxygenation (90 %) with the lowest rate of complications, where aggressive hypervolemic hypertension treatment increased brain tissue oxygenation 60 % and hypervolemia resulted with highest risk and lowest benefit for the patients (24).
Muench et al. investigated the effects of triple H therapy, regarding the results on regional blood flow, intracranial pressure and brain tissue oxygenation in animals and patients who experienced SAH. Vasopressors and colloids were used to establish the three components of triple H therapy. They observed that regional cerebral blood flow improved with induced hypertension and hypervolemia but further increases of cerebral blood flow did not lead to an improvement in brain tissue oxygenation compared to induced hypertension alone. That is, the oxygen carrying capacity diminishes as Hct levels decline with hypervolemia, and hypervolemia should be applied with caution due to increased risk of complications (18) .
In the study of Mocco et al, fluids were used to achieve volume expansion and increase cardiac output. The increase in cardiac
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However, several studies reported a specificity of 98% to 100 % and sensitivity of 58% to 85 % for detection of angiographic vasospasm by TCD ultrasonography (8,23).
ConCLuSIon
Hypervolemia treatment may be associated with complications. More studies are needed to determine the risk-benefit ratio of hypervolemia. Normovolemia and hypertension may be an effective method to overcome vasospasm in SAH, especially in patients where the autoregulation is not preserved. Aggressive hypervolemia treatment may help to increase flow velocities and manage vasospasm, however, risk-benefit ratio is questionable and the decision to use hypervolemia should be based on the clinical situation of the patient. That is, hypervolemia should be employed on the individualised basis. It has intracranial and extracranial complications, in the study population three patients presented hyponatremia and one patient had to be treated for pulmonary edema. Cerebral ischemia was detected in CT scans of 5 HHT patients and 4 HNT patients. Hypervolemia is maintained with colloids, low molecular weight dextran, blood, albumin and hetastarch. In this study albumin 5% was infused to obtain volume expansion and blood transfusion was not performed with Hct values greater than 30 %. In our results, there was no difference in hemodilution between the groups ( Figure 5 ). Hyperglycemia is accepted as a risk factor for outcome in SAH patients. The number of patients requiring insulin infusion for hyperglycemia management was similar in both groups. In the means of GOS observed after 3 months, there was not difference between hypervolemia or normovolemia treated patients (Table I ).
The limitation of this study is that it is designed as a retrospective and prospective study without randomization of the patients. The protocol performed for SAH patients was hypervolemia and hypertension; however, the treatment protocol performed consisted complications of hyponatremia in three patients and pulmonary edema in one patient. Hypertension could not be attained with hypervolemia; induced hypertension was required in most of the patients. In the rest of the patients, normovolemia and induced hypertension were performed. In our patient population they had no cardiac or pulmonary diseases so CVP catheters were inserted instead of Swan Ganz catheters. Although the study started with the three components of triple-H therapy, administration of high volumes seemed not to make any difference in outcome and symptomatic vasospasm and in the rest of the patients, normovolemia was aimed.
Although we used CT scans and TCD ultrasonography to exclude other causes of neurologic deterioration, angiography was not performed to confirm a diagnosis of vasospasm.
